SCNI
Scinai Immunotherapeutics Ltd. (SCNI) Economic Moat Analysis (2026)
No material changes this month.
Intangible Assets
SCNI’s negative TTM ROIC and ROCE indicate it is not converting any apparent brand, regulatory, or product differentiation into durable economic rents versus peers.
The absence of disclosed 5-year margin or return history in the provided metrics limits evidence of persistent intangible advantage, while stronger peers typically show positive, repeatable returns that support pricing power.
No filing-based evidence was provided for proprietary IP, regulated licenses, or brand-led customer preference that would materially defend margins over a 5–10 year horizon.
Relative to peers, the current profitability profile suggests any intangible assets are either weak, non-exclusive, or insufficient to offset competitive pressure.
Switching Costs
Negative ROIC alongside very low asset turnover suggests customers are not locked in by high switching frictions that would preserve returns versus peers.
The provided data do not show recurring revenue, contract stickiness, or workflow dependence that would make replacement costly for customers.
If switching costs were meaningful, SCNI would typically sustain positive capital returns better than peers, but the current metrics point to the opposite.
On a peer-relative basis, the evidence supports low retention power and limited pricing protection from customer lock-in.
Network Effects
The metrics provided do not indicate a user, data, or ecosystem flywheel that would make SCNI more valuable as adoption rises relative to peers.
Negative capital returns are inconsistent with a network-driven moat that usually improves monetization, retention, or unit economics over time.
No filing evidence was provided for platform dependency, multi-sided participation, or industry-standard status that would create peer-dependent demand.
Compared with peers that benefit from network effects, SCNI shows no observable structural advantage in the supplied data.
Cost Advantage
SCNI’s negative ROIC and ROCE imply it is not operating with a durable cost advantage that translates into superior returns versus peers.
The very low asset turnover suggests the business is not extracting strong productivity from its asset base, which weakens any claim to structural cost leadership.
No evidence was provided of scale purchasing, lower unit costs, or process advantages that would sustain margin resilience over 5–10 years.
Relative to peers, the current metrics point to a cost structure that is not advantaged enough to defend pricing or profitability.
Efficient Scale
The supplied data do not show evidence that SCNI operates in a niche where limited market size protects returns through efficient scale.
Negative returns suggest the company is not benefiting from a stable oligopoly or natural-monopoly-like structure that would restrain competitive entry.
No filing-based evidence was provided that the market is too small for multiple efficient competitors or that SCNI controls a scarce bottleneck asset.
Versus peers, the current profile looks more like a contested business than one protected by efficient scale.
Overall Score
SCNI shows no clear durable moat in the provided evidence, because negative TTM returns and weak asset productivity do not support pricing power, retention, or structural cost advantage versus peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Scinai Immunotherapeutics Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
